LG and Samsung's middle-of-the-road OLEDs serve as the crème de la crème for most consumers, but which one has the slight edge?

JUVÉDERM ® VOLUMA ® XC is the One and Only Hyaluronic Acid Dermal Filler Indicated to Treat Cheeks, Chin, and Now Moderate to Severe Temple Hollowing 1,2 Only Allergan Aesthetics, the Makers of BOTOX ...

JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing is Now Available Nationwide. Actual patient treated with 2.9 mL of JUVÉDERM® VOLUMA® XC in the temples, 2.1 mL of JUVÉDERM ...

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM® VOLUMA® XC for temple hollowing. Following its U.S. FDA approval in March 2024, JUVÉDERM® VOLUMA® ...

With Juvederm Voluma, patients look rested and refreshed, never pulled or plastic. The best candidates for Juvederm Voluma are patients in their 30s-60s who want long-lasting restoration to sinking ...

The FDA has approved Juvéderm Voluma XC for the improvement of moderate to severe temple hollowing in the temple region in patients aged great than 21 years.

"The approval of JUVÉDERM ® VOLUMA ® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, ...

--Today, Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of JUVÉDERM ® VOLUMA ® XC for injection in the temple region to improve moderate to severe temple hollowing in ...

Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm Voluma XC to treat moderate to severe temple hollowing in adults over 21 years of age. According to the company, ...

Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age ...